In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Unity Biotechnology (UBX – Research Report), with a price target of $12.00. The company’s shares closed last Monday at $1.02, close to its 52-week low of $1.00.
According to TipRanks.com, Fein is ranked 0 out of 5 stars with an average return of -3.2% and a 34.8% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Amylyx Pharmaceuticals, Inc., and Deciphera Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Unity Biotechnology with a $6.75 average price target, which is a 530.8% upside from current levels. In a report issued on February 4, Mizuho Securities also maintained a Buy rating on the stock with a $7.00 price target.
Based on Unity Biotechnology’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $16.45 million. In comparison, last year the company had a GAAP net loss of $27.55 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Unity Biotechnology, Inc. operates as a biotechnology company engaged in the research and development of therapeutics to extend the human health span. The company was founded by Nathaniel David, Jan van Deursen, Judith Campisi and Daohong Zhou in March 2009 and is headquartered in Brisbane, CA.
Read More on UBX: